ClinicalTrials.gg
CompletedNCT06922305Updated Apr 22, 2025

Relative Bioavailability Study of HR19042 in Healthy Subjects

A Phase 1 interventional study of HR19042 Capsule, Tarpeyo®, Budenofalk® in Primary IgA Nephropathy; Autoimmune Hepatitis, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-22.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Diagnostic

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Dec 2023, registered Apr 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Glomerulonephritis, IGA by Jiangsu HengRui Medicine Co., Ltd. — 3 open to participants now, 3 under way, 1 of them phase 3. Glomerulonephritis, IGA · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
8th of 11
18 · median 61
Started
2023
with 2 others
Phase 1
5 of 11
none open now
Registered
7th of 11
by date

Among the 11 studies in Glomerulonephritis, IGA by Jiangsu HengRui Medicine Co., Ltd., this one is the 8th largest by enrollment, is one of 3 that started in 2023, is one of 5 in phase 1, and was the 7th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

3 of the 11 studies in Glomerulonephritis, IGA by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Glomerulonephritis, IGA by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This is a single-center, randomized, open-label, three-period, dual Latin square crossover study.

Primary Objective:

  1. To evaluate the oral relative bioavailability of HR19042 Capsules compared with budesonide delayed-release capsules (Tarpeyo®) and budesonide enteric-coated capsules (Budenofalk®).

    Secondary Objective

  2. To assess safety following administration.
03

Conditions studied

  • Primary IgA Nephropathy; Autoimmune Hepatitis
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects, ages 18 to 45, inclusive, at the time of .
  2. Female subjects weigh ≥ 45 kg, male subjects weigh ≥ 50 kg, and between 19.0 and 28.0 kg/m2, inclusive, at screening.
  3. Understands the study procedures in the informed consent form ICF and be willing and able to comply with the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Subject with any history of severe allergic or anaphylactic reactions to any allergen including drugs, or allergic disease diagnosed and treated by a physician.
  2. history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine or connective tissue diseases or disorders
  3. Subject has positive results at screening for (HIV), surface antigen (HBsAg), virus (HCV), or treponema pallidum antibody.
  4. History of any gastrointestinal surgery or cholecystectomy that could impact the PK of study drugs.
  5. Participated in other clinical trials within 3 months before screening or plan to participate in other clinical trials during this study.
  6. Blood loss or blood donation of more than 300 mL within 3 months before screening, or intended to donate blood during the trial.
  7. Those who have been vaccinated with vaccines within 3 month before screening or who have an intention to vaccinate during the trial.
  8. Difficulty in venous blood sampling or fear of needles/blood.
  9. Difficulty in swallowing capsules, or inability to comply with the provided diet and study-related instructions.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Sequence 1

    Period 1: HR19042 Capsules Period 2: Tarpeyo® Period 3: Budenofalk®

    Drug: HR19042 Capsule, Tarpeyo®, Budenofalk®

  • Experimental
    Sequence 2

    Period 1: Tarpeyo® Period 2: Budenofalk® Period 3: HR19042 Capsules

    Drug: HR19042 Capsule, Tarpeyo®, Budenofalk®

  • Experimental
    Sequence 3

    Period 1: Budenofalk® Period 2: HR19042 Capsules Period 3: Tarpeyo®

    Drug: HR19042 Capsule, Tarpeyo®, Budenofalk®

  • Experimental
    Sequence 4

    Period 1: Tarpeyo® Period 2: HR19042 Capsules Period 3: Budenofalk®

    Drug: HR19042 Capsule, Tarpeyo®, Budenofalk®

  • Experimental
    Sequence 5

    Period 1: HR19042 Capsules Period 2: Budenofalk® Period 3: Tarpeyo®

    Drug: HR19042 Capsule, Tarpeyo®, Budenofalk®

  • Experimental
    Sequence 6

    Period 1: Budenofalk® Period 2: Tarpeyo® Period 3: HR19042 Capsules

    Drug: HR19042 Capsule, Tarpeyo®, Budenofalk®

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax: Maximum plasma concentration. Blood samples will be collected.

    Time frame: From Day 1 up to Day 8

  2. AUC0-t: Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration. Blood samples will be collected.

    Time frame: From Day 1 up to Day 8

  3. AUC0-∞: Area under the plasma concentration-time curve from time 0 to infinity. Blood samples will be collected.

    Time frame: From Day 1 up to Day 8

  4. Tmax: Observed time to reach Cmax. Blood samples will be collected.

    Time frame: From Day 1 up to Day 8

Secondary outcomes

  1. Incidence of treatment emergent AEs (TEAEs)

    Time frame: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 14)

07

Study locations

1 site
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610072, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Jan 2024, 0 months.

Of 22 phase 1 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2025
First posted
Apr 10, 2025
StartActual
Dec 27, 2023
Primary completionActual
Jan 25, 2024
CompletionActual
Jan 25, 2024
Last update
Apr 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06922305
Responsible party
Sponsor
First posted
Apr 10, 2025
Start date
Dec 27, 2023
Primary completion
Jan 25, 2024
Completion
Jan 25, 2024
Last update
Apr 22, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HR19042

Start the discussion